

November 11, 2025

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Receipt of Award Notification from Pan American Health Organization (“PAHO”) under a Long-Term Agreement for supply of Easyfive-TT worth ~US\$ 4.75 million for CY2026 and CY2027

Reg: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we are delighted to inform you that Panacea Biotec Limited (“the Company”) has received an Award notification from PAHO under a Long-Term Agreement for supply of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine (Pentavalent) - Liquid (single dose) (“**Easyfive-TT**”) to PAHO, valid until December 31, 2027.

The total award to the Company is for supply of Easyfive-TT Vaccine aggregating ~US\$ 4.75 million (~Rs.41 Crore) during Calendar Year 2026 and 2027.

The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and other circulars as may be applicable from time to time, is annexed herewith as **Annexure A**.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

Vinod Goel
Group CFO and Head Legal
& Company Secretary

Annexure – A

Details required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/CFD/PoD2/CIR/P/0155 dated November 11, 2024

#	Particulars	Details
a.	Name of the entity awarding the order(s) / contract(s)	Pan American Health Organization, Regional Office of World Health Organization (PAHO)
b.	Significant terms and conditions of order(s)/contract(s) awarded in brief	Award for supply of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine (Pentavalent) - Liquid (1 dose) (“Easyfive-TT”) worth ~US\$ 4.75 million during Calendar Year 2026 and 2027
c.	Whether order(s) / contract(s) have been awarded by domestic / international entity	International
d.	Nature of order(s) / contract(s)	Supply of Easyfive-TT Vaccine to PAHO for its requirements as per the orders as may be received from time to time.
e.	Whether domestic or international	International
f.	Time period by which the order(s) / contract(s) is to be executed	Calendar Year 2026 and 2027
g.	Broad consideration or size of the order(s) / contract(s)	~US\$ 4.75 million (~Rs.41 Crore)
h.	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s) / contract(s)? If yes, nature of interest and details thereof	No
i.	Whether the order(s) / contract(s) would fall within related party transactions? If yes, whether the same is done at “arm’s length”	No

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotech Limited**

Vinod Goel

Group CFO and Head Legal & Company Secretary